9F2I
Crystal structure of SARS-CoV-2 N-protein C-terminal domain in complex with 2-amino-1,3-benzothiazol-6-ol
This is a non-PDB format compatible entry.
Summary for 9F2I
Entry DOI | 10.2210/pdb9f2i/pdb |
Related | 9F2G 9F2H |
Descriptor | Nucleoprotein, 2-amino-1,3-benzothiazol-6-ol, SULFATE ION, ... (5 entities in total) |
Functional Keywords | ctd, sars-cov-2 nucleocapsid, covid-19, riluzole, benzothiazols, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 |
Total number of polymer chains | 8 |
Total formula weight | 100989.48 |
Authors | Marquez-Monino, M.A.,Gonzalez, B.,Perez-Canadillas, J.M. (deposition date: 2024-04-23, release date: 2024-11-13) |
Primary citation | Marquez-Monino, M.A.,Santiveri, C.M.,de Leon, P.,Camero, S.,Campos-Olivas, R.,Jimenez, M.A.,Saiz, M.,Gonzalez, B.,Perez-Canadillas, J.M. The ALS drug riluzole binds to the C-terminal domain of SARS-CoV-2 nucleocapsid protein and has antiviral activity. Structure, 2024 Cited by DOI: 10.1016/j.str.2024.10.025PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.45 Å) |
Structure validation
Download full validation report